Accelerate the Discovery, Validation and Clinical Translation of Novel and Rationally Designed Molecular Glues through Systematic Screening, Expanding Ligase Toolbox and Optimizing Pharmacological Properties

The 2nd Molecular Glue Drug Development Summit 2024

Uniting Large Pharma, Innovative Biotech & Leading Academics Dedicated to Accelerating the Next-Generation of Molecular Glues into the Clinic

Molecular glue development continues to gain exponential momentum, with advances in screening tools, identification assays and structure-based design. With numerous strategic collaborations and investments into rationale drug discovery, the molecular glue field is propelling the clinical progression of next-generation molecular glue candidates across a spectrum of indications and undruggable targets.

Owing to this, the 2nd Molecular Glue Drug Development Summit returns as the world’s only fully molecular glue-dedicated meeting, uniting 80+ glue experts devoted to accelerating the discovery and development of novel, rationally designed and therapeutically validated glues for patients in need.

What’s New for 2024?

Molecular Glue Drug Development Summit

Extensive content covering the latest advances in rational glue screening, biochemical optimization and progressing the wave of next-generation molecular glues into pre-clinical and clinical settings.

Molecular Glue Drug Development Summit

A new cohort of expert speakers and companies presenting from the likes of Neomorph, GSK, Lyterian Therapeutics & Gandeeva Therapeutics

Molecular Glue Drug Development Summit

An expert-led pre-conference workshop day addressing hurdles across the molecular glue development pipeline including artificial intelligence, the proteomics workflow and best pre-clinical and IND filing practices to accelerate translation and development of novel molecular glues for patients.

2024 Expert Speakers Include:

40974 - Christian Ottmann - Ambagon
40974 - Lena Dolgikh - Monte Rosa

Christian Ottmann
Founder & Chief
Technology Officer

Ingrid Wertz
Chief Executive
Officer & Co-Founder

Lena Dolgikh
Head of Computer-
Aided Drug Design
Monte Rosa

40974 - Patrrick Arsenault - TRIANA
40974 - Sriram Subramaniam - Gandeeva
40974 - Shanique Alabi - GSK

Patrick Arsenault
Director- Lead
Triana Biomedicines

Sriram Subramaniam
Founder & Chief Executive Officer
Gandeeva Therapeutics

Shanique Alabi
Principal Investigator

Companies Attending in 2024 Include:

mRNA (1)

2024 Partners:

Expertise Partner


Other Events in the Small Molecules & TPD World Series: